Table 1.
Demographic and clinical characteristics in patients with AQP4 + NMOSD and HCs at MRI-1.
| AQP4 + NMOSD (N = 29) | HCs (N = 29) | P-value | |
|---|---|---|---|
| Demographic | |||
| Female (%) | 22/29 (75.9%) | 22/29 (75.9%) | 1.00 |
| Age (years) | 59.0 [9.5] (34–73) | 61.0 [4.5] (33–73) | 0.24 |
| Clinical | |||
| Age at disease onset | 48.0 [19.0] (19–67) | ||
| Disease duration (years) | 7.0 [13.4] (0.3–42.9) | ||
| EDSS score | 3.5 [4.0] (1.0–9.0) | ||
| ARR from disease onset | 0.4 [0.4] (0.2–4.0) | ||
| Years from last attack | 2.8 [3.3] (0.2–6.9) | ||
| Years of continuous prednisolone | 3.9 [3.2] (0.1–8.8) (N = 24) | ||
| Years of relapse prevention treatment | 1.3 [1.8] (0.1–5.2) | ||
| Oligoclonal bands positivity | 2/17 (11.8%) | ||
| Number of patients with a history of | |||
| Optic neuritis | 20/29 (69.0%) | ||
| Myelitis | 25/29 (86.2%) | ||
| Myelitis with long cord lesion | 18/29 (62.1%) | ||
| Brainstem lesion | 6/29 (20.7%) | ||
| Area postrema syndrome | 1/29 (3.4%) | ||
| Cerebral syndrome | 4/29 (13.7%) | ||
| Treatment | |||
| Prednisolone | 20 | ||
| Prednisolone + azathioprine | 3 | ||
| Prednisolone + eculizumab | 1 | ||
| None | 5 | ||
Data are presented as median number (%) or [interquartile range] (range). *P < 0.05. Years of the relapse prevention treatment indicate the continuous relapse prevention treatment period at the same dosage which was given at MRI-1.
AQP4 + NMOSD anti-aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder disease, ARR annualized relapse rate, EDSS Kurtzke’s Expanded Disability Status Scale.